Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease

NCT05388149 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT05388149
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05388149 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease
Lead sponsor
University Health Network, Toronto
Phase
Phase 2
Overall status
Recruiting
Start date
December 6, 2022
Completion date
July 31, 2027
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, her2-positive breast cancer